Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

(2011) Teri N. Kreisl et al.   NEURO-ONCOLOGY

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer

(2009) A.-R. Hanauske et al.   ANNALS OF ONCOLOGY

Cetuximab Attenuates Metastasis and u-PAR Expression in Non-Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity

(2009) D. A. Nikolova et al.   CANCER RESEARCH

Role of PKCβ in hepatocellular carcinoma cells migration and invasion in vitro: a potential therapeutic target

(2009) Kun Guo et al.   CLINICAL & EXPERIMENTAL METASTASIS

Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)

(2009) Elisa Giovannetti et al.   CURRENT DRUG TARGETS

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Protein kinases C isozymes are differentially expressed in human breast carcinomas

(2009) Shadan Ali et al.   LIFE SCIENCES

The Expression of RNA-Binding Protein HuR in Non-Small Cell Lung Cancer Correlates with Vascular Endothelial Growth Factor-C Expression and Lymph Node Metastasis

(2009) Jun Wang et al.   ONCOLOGY

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells

(2008) C Tekle et al.   BRITISH JOURNAL OF CANCER

Enzastaurin, a Protein Kinase C  Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells

(2008) K.-W. Lee et al.   CANCER RESEARCH

Evolving role of uPA/uPAR system in human cancers

(2008) Kathleen Dass et al.   CANCER TREATMENT REVIEWS

Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian Cancer

(2008) E. Henic et al.   CLINICAL CANCER RESEARCH

Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cβ inhibitor, in non-small cell lung cancer cells

(2008) Floriana Morgillo et al.   MOLECULAR CANCER THERAPEUTICS